tert-Butyl 4-(4-chloro-5-methylpyrimidin-2-yl)piperazine-1-carboxylate

Catalog No.: 
ACRPUG775
CAS No.: 
1261236-07-0
Molecular Formula: 
C14H21ClN4O2
Molecular Weight: 
312.80
tert-Butyl 4-(4-chloro-5-methylpyrimidin-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$620.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-chloro-5-methylpyrimidin-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-chloro-5-methylpyrimidin-2-yl)piperazine-1-carboxylate
Molecular FormulaC14H21ClN4O2
Molecular Weight312.80
SMILESO=C(N1CCN(C2=NC=C(C)C(Cl)=N2)CC1)OC(C)(C)C
InChI KeyFCVACVPKAJGXFB-UHFFFAOYSA-N
Synonymtert-Butyl 4-(4-chloro-5-methylpyrimidin-2-yl)piperazine-1-carboxylate
CAS No.1261236-07-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACRPUG775 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRPUG775 route product structure diagram
    ACRPUG7751261236-07-0
Inquiry

2. ACRPUG775 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRPUG775 route product structure diagram
    ACRPUG7751261236-07-0
Inquiry

3. ACRPUG775 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRPUG775 route product structure diagram
    ACRPUG7751261236-07-0
Inquiry

Comments (0)